Erratum: Neuroendocrine neoplasms of the gut and pancreas: New insights (Nature Reviews Endocrinology (2012) 8 (54-64) DOI:10.1038/nrendo.2011.120);Neuroendocrine neoplasms of the gut and pancreas: New insights

Nature Reviews Endocrinology

Volumn 8, Issue 1, 2012, Pages 54-64

  Rindi, Guido ^a   Wiedenmann, Bertram ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; ENEMA; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GALLIUM 68; INDIUM 111; KI 67 ANTIGEN; LUTETIUM 177; NEURON SPECIFIC ENOLASE; OXALIPLATIN; PLATINUM DERIVATIVE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; STREPTOZOCIN; SUNITINIB; SYNAPTOPHYSIN; TECHNETIUM 99M; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; TRACER; TUMOR MARKER;

APPENDIX TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CAPSULE ENDOSCOPY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GASTROSCOPY; HISTOLOGY; HUMAN; INTESTINE ENDOSCOPY; LABORATORY TEST; LARGE INTESTINE TUMOR; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE TUMOR; STOMACH TUMOR; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR SCINTISCANNING; ULTRASOUND; WORLD HEALTH ORGANIZATION;

EID: 83555173348     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.229     Document Type: Erratum

References (106)

1. Yao, J. C. et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063-3072 (2008).
2. Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T. & Snyderwine, E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J. Natl Cancer Inst. 100, 1282-1289 (2008).
3. Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. (Eds) WHO Classification of Tumours of the Digestive System 4th edn Vol. 3 (IARC Press, Lyon, 2010).
4. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
5. Raymond, E., Faivre, S., Hammel, P. & Ruszniewski, P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target. Oncol. 4, 253-254 (2009).
6. Solcia, E., Rindi, G. & Capella, C. in Histochemistry in Pathology 2nd edn (eds Felipe, M. I. & Lake, B. D.) 397-409 (Churchill-Livingstone, Edinburgh, 1990).
7. Wiedenmann, B. & Huttner, W. B. Synaptophysin and chromogranins/secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 58, 95-121 (1989).
8. Wiedenmann, B. et al. Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenterology 95, 1364-1374 (1988).
9. Adams, M. S. & Bronner-Fraser, M. Review: The role of neural crest cells in the endocrine system. Endocr. Pathol. 20, 92-100 (2009).
10. Schonhoff, S. E., Giel-Moloney, M. & Leiter, A. B. Minireview: Development and differentiation of gut endocrine cells. Endocrinology 145, 2639-2644 (2004).
11. Lepage, C., Rachet, B. & Coleman, M. P. Survival from malignant digestive endocrine tumors in England and Wales: A population-based study. Gastroenterology 132, 899-904 (2007).
12. Soga, J. & Tazawa, K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 28, 990-998 (1971).
13. Arrigoni, M. G., Woolner, L. B. & Bernatz, P. E. Atypical carcinoid tumors of the lung. J. Thorac. Cardiovasc. Surg. 64, 413-421 (1972).
14. Modlin, I. M. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61-72 (2008).
15. Zerbi, A. et al. Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in Italy of 297 sporadic cases. Am. J. Gastroenterol. 105, 1421-1429 (2010).
16. Oberndorfer, S. Karzinoide Tumoren des Dünndarms. Frankf Z. Pathol. Int. 1, 425-432 (1907).
17. Rindi, G., Capella, C. & Solcia, E. in Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors (eds Mignon, M. & Colombel, J. F.) 177-191 (John Libbey Eurotext, Montrouge, 1999).
18. Gould, V. E. Neuroendocrinomas and neuroendocrine carcinomas: APUD cell system neoplasms and their aberrant secretory activities. Pathol. Annu. 12, 33-62 (1977).
19. Gould, V. E. & Chejfec, G. Ultrastructural and biochemical analysis of "undifferentiated" pulmonary carcinomas. Hum. Pathol. 9, 377-384 (1978).
20. Travis, W. D. et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 15, 529-553 (1991).
21. Rindi, G. et al. in WHO Classification of Tumours of the Digestive System 4th edn Vol. 3 (eds Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D.) 10-12 (IARC Press, Lyon, 2010).
22. Solcia, E., Klöppel, G. & Sobin, L. H. World Health Organization International Histological Classification of Tumours: Histological Typing of Endocrine Tumours 2nd edn (Springer-Verlag, New York, 2000).
23. Rindi, G. et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 449, 395-401 (2006).
24. Rindi, G. et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 451, 757-762 (2007).
25. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. (eds) TNM Classification of Malignant Tumours 7th edn (Wiley-Blackwell, Chichester, 2009).
26. Edge, S. B. et al. (eds) AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
27. Yang, Q., Bermingham, N. A., Finegold, M. J. & Zoghbi, H. Y. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294, 2155-2158 (2001).
28. Jenny, M. et al. Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium. EMBO J. 21, 6338-6347 (2002).
29. Desai, S. et al. Nkx2.2 regulates cell fate choice in the enteroendocrine cell lineages of the intestine. Dev. Biol. 313, 58-66 (2008).
30. Rindi, G. et al. Targeted ablation of secretin-producing cells in transgenic mice reveals a common differentiation pathway with multiple enteroendocrine cell lineages in the small intestine. Development 126, 4149-4156 (1999).
31. Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41-46 (2004).
32. Xu, X. et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132, 197-207 (2008).
33. Puri, S. & Hebrok, M. Cellular plasticity within the pancreas-lessons learned from development. Dev. Cell 18, 342-356 (2010).
34. Lichtenauer, U. D. & Beuschlein, F. The tumor stem cell concept-implications for endocrine tumors? Mol. Cell. Endocrinol. 300, 158-163 (2009).
35. Thomas, D., Friedman, S. & Lin, R. Y. Thyroid stem cells: Lessons from normal development and thyroid cancer. Endocr. Relat. Cancer 15, 51-58 (2008).
36. Powers, J. F., Evinger, M. J., Zhi, J., Picard, K. L. & Tischler, A. S. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 147, 928-937 (2007).
37. Zhang, P., Zuo, H., Ozaki, T., Nakagomi, N. & Kakudo, K. Cancer stem cell hypothesis in thyroid cancer. Pathol. Int. 56, 485-489 (2006).
38. Heiskala, K., Arola, J., Heiskala, M. & Andersson, L. C. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol. Histopathol. 25, 63-72 (2010).
39. van Eeden, S. et al. Goblet cell carcinoid of the appendix: A specific type of carcinoma. Histopathology 51, 763-773 (2007).
40. Westerman, B. A. et al. Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors. Int. J. Biol. Markers 22, 114-123 (2007).
41. Schmitt, A. M. et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am. J. Surg. Pathol. 32, 420-425 (2008).
42. Lejonklou, M. H., Edfeldt, K., Johansson, T. A., Stålberg, P. & Skogseid, B. Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells. Pancreas 38, 259-266 (2009).
43. Garcia-Carbonero, R. et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794-1803 (2010).
44. Ito, T. et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234-243 (2010).
45. Niederle, M. B., Hackl, M., Kaserer, K. & Niederle, B. Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr. Relat. Cancer 17, 909-918 (2010).
46. Hruban, R. H., Bishop Pitman, M. & Klimstra, D. S. Tumors of the Pancreas 6th edn (American Registry of Pathology Press, Washington DC, 2007).
47. Klöppel, G. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90, 162-166 (2009).
48. Klimstra, D. S. et al. Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am. J. Surg. Pathol. 34, 300-313 (2010).
49. Volante, M., Rindi, G. & Papotti, M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: A comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 449, 499-506 (2006).
50. Tönnies, H. et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48, 536-541 (2001).
51. Pizzi, S. et al. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 98, 1273-1282 (2003).
52. Furlan, D. et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin. Cancer Res. 10, 947-957 (2004).
53. Kim do, H. et al. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 47, 84-92 (2008).
54. Missiaglia, E. et al. Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245-255 (2010).
55. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
56. Löllgen, R. M., Hessman, O., Szabo, E., Westin, G. & Akerström, G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int. J. Cancer 92, 812-815 (2001).
57. Wang, G. G. et al. Comparison of genetic alterations in neuroendocrine tumors: Frequent loss of chromosome 18 in ileal carcinoid tumors. Mod. Pathol. 18, 1079-1087 (2005).
58. Cunningham, J. L. et al. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer 50, 82-94 (2011).
59. Rigaud, G. et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implications. Cancer Res. 61, 285-292 (2001).
60. Jonkers, Y. M. et al. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocrine Relat. Cancer 14, 769-779 (2007).
61. Calender, A. in Handbook of Neuroendocrine Tumours (eds Caplin, M. & Kvols, L.) 55-81 (Bioscientifica, Bristol, 2006).
62. de Herder, W. W. et al. Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 84, 183-188 (2006).
63. Jensen, R. T. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84, 173-182 (2006).
64. Eriksson, B. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8-19 (2008).
65. Jensen, R. T. in Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumours (eds Mignon, M. & Colombel, J. F.) 192-219 (John Libbey Eurotext, Paris, 1999).
66. Modlin, I. M. et al. Gastrointestinal neuroendocrine (carcinoid) tumours: Current diagnosis and management. Med. J. Aust. 193, 46-52 (2010).
67. Yao, J. C. et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J. Clin. Oncol. 28, 69-76 (2010).
68. Massironi, S. et al. Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors. Am. J. Gastroenterol. 105, 2072-2078 (2010).
69. Rufini, V., Calcagni, M. L. & Baum, R. P. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36, 228-247 (2006).
70. Scarsbrook, A. F. et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 27, 455-477 (2007).
71. Elsayes, K. M. et al. Imaging of carcinoid tumors: Spectrum of findings with pathologic and clinical correlation. J. Comput. Assist. Tomogr. 35, 72-80 (2011).
72. Kwekkeboom, D. J. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 90, 184-189 (2009).
73. Sundin, A., Vullierme, M. P., Kaltsas, G. & Plöckinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological examinations. Neuroendocrinology 90, 167-183 (2009).
74. Kiesslich, R. et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 133, 1769-1778 (2007).
75. May, A. et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: A comparative, prospective, and blinded trial. Gut 53, 634-640 (2004).
76. Swain, P. & Fritscher-Ravens, A. Role of video endoscopy in managing small bowel disease. Gut 53, 1866-1875 (2004).
77. Moglia, A., Menciassi, A., Dario, P. & Cuschieri, A. Capsule endoscopy: Progress update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 6, 353-362 (2009).
78. Carrasquillo, J. A. & Chen, C. C. Molecular imaging of neuroendocrine tumors. Semin. Oncol. 37, 662-679 (2010).
79. Kwekkeboom, D. J. et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, R53-R73 (2010).
80. Ambrosini, V., Tomassetti, P., Franchi, R. & Fanti, S. Imaging of NETs with PET radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging 54, 16-23 (2010).
81. Putzer, D. et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-l-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q. J. Nucl. Med. Mol. Imaging 54, 68-75 (2010).
82. Yao, J. C. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 21, 163-172 (2007).
83. Strosberg, J. R. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117, 268-275 (2011).
84. Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 27, 4656-4663 (2009).
85. Pape, U. F. et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113, 256-265 (2008).
86. Jann, H. et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer 117, 3332-3341 (2011).
87. de Herder, W. W., O'Toole, D., Rindi, G. & Wiedenmann, B. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors Part 1-Stomach, Duodenum and Pancreas. Neuroendocrinology 84, 151-216 (2006).
88. de Herder, W. W., O'Toole, D., Rindi, G. & Wiedenmann, B. ENETS Consensus Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumors Part 2-Midgut and Hindgut Tumors. Neuroendocrinology 87, 1-63 (2008).
89. Oberg, K. E., Reubi, J. C., Kwekkeboom, D. J. & Krenning, E. P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139, 742-753 (2010).
90. Roberts, W. C. A unique heart disease associated with a unique cancer: Carcinoid heart disease. Am. J. Cardiol. 80, 251-256 (1997).
91. Dumoulein, M. et al. Carcinoid heart disease: Case and literature review. Acta Cardiol. 65, 261-264 (2010).
92. Schmidt, C., Bloomston, M. & Shah, M. H. Well-differentiated neuroendocrine tumors: A review covering basic principles to loco-regional and targeted therapies. Oncogene 30, 1497-1505 (2011).
93. Ahmadzadehfar, H., Biersack, H. J. & Ezziddin, S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin. Nucl. Med. 40, 105-121 (2010).
94. Crocetti, L. & Lencioni, R. Radiofrequency ablation of pulmonary tumors. Eur. J. Radiol. 75, 23-27 (2010).
95. Wiedenmann, B., Pavel, M. & Kos-Kudla, B. From targets to treatments-a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology (in press).
96. Bertino, E. M., Confer, P. D., Colonna, J. E., Ross, P. & Otterson, G. A. Pulmonary neuroendocrine/carcinoid tumors: A review article. Cancer 115, 4434-4441 (2009).
97. Bajetta, E. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59, 637-642 (2007).
98. Ceppi, P. et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin. Cancer Res. 14, 1059-1064 (2008).
99. O'Toole, D. et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, 847-856 (2010).
100. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
101. Kulke, M. H. et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15, 338-345 (2009).
102. Hlatky, R., Suki, D. & Sawaya, R. Carcinoid metastasis to the brain. Cancer 101, 2605-2613 (2004).
103. Pool, S. E. et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med. 40, 209-218 (2010).
104. Bushnell, D. L. Jr et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652-1659 (2010).
105. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124-2130 (2008).
106. Nilsson, O., Arvidsson, Y., Johanson, V., Forssell-Aronsson, E. & Ahlman, H. New medical strategies for midgut carcinoids. Anticancer Agents Med. Chem. 10, 250-269 (2010).